Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.35 USD | +7.31% | +6.82% | +88.00% |
04-16 | Lexaria Obtains Ethics Review Board Approval to Start New GLP-1 Study | MT |
04-16 | Lexaria Bioscience Corp. Receives Ethics Review Board Approval to Begin New GLP-1 Study | CI |
Sales 2024 * | 482K 658K | Sales 2025 * | 488K 666K | Capitalization | 30.28M 41.39M |
---|---|---|---|---|---|
Net income 2024 * | -6M -8.2M | Net income 2025 * | -7M -9.57M | EV / Sales 2024 * | 62.9 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 62.1 x |
P/E ratio 2024 * |
-4.39
x | P/E ratio 2025 * |
-4.75
x | Employees | 5 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.42% |
1 day | +7.31% | ||
1 week | +6.82% | ||
Current month | -35.26% | ||
1 month | -36.66% | ||
3 months | +65.49% | ||
6 months | +102.59% | ||
Current year | +88.00% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 62 | 06-10-25 | |
John Docherty
PSD | President | 53 | 15-04-14 |
George Jurcic
IRC | Investor Relations Contact | - | 21-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 62 | 06-10-25 | |
Nicholas Baxter
BRD | Director/Board Member | 70 | 11-07-07 |
Albert Reese
BRD | Director/Board Member | 74 | 21-01-13 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 2.35 | +7.31% | 172,106 |
24-04-25 | 2.19 | -0.45% | 22,122 |
24-04-24 | 2.2 | -1.79% | 98,910 |
24-04-23 | 2.24 | -1.10% | 53,986 |
24-04-22 | 2.265 | +2.95% | 34,458 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+88.00% | 30.28M | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- LEXX Stock